

**Proposed Amendments to the Claims**

The following listing of the claims will replace all prior versions and listings of claims in the application.

1-27 (Canceled)

28. (Previously Presented) A monoclonal antibody which specifically binds to a 40-O-(2-hydroxyethyl)-rapamycin with a cross reactivity with rapamycin of less than 30%.

29-30. (Canceled)

31. (Previously Presented) A monoclonal antibody of claim 28, obtained by

- a) reaction of a 40-O-(2-hydroxyethyl) rapamycin having an activated coupling group at the 28-O position with an immunogenic protein to produce an immunogenic conjugate;
- b) administration of said immunogenic conjugate to an appropriate animal species to effect immunogenic challenge and recovery of antibody-producing cells sensitized to said conjugate;
- c) immortalization of said antibody producing cells; and
- d) recovery of monoclonal antibody from a selected immortalized cell line thus established.

32.-37 (Canceled)

38. (Previously Presented) A hybridoma cell line which produces a monoclonal antibody of claim 28.

39. (Previously Presented) An immunoassay kit for measuring the blood level of a rapamycin comprising a monoclonal antibody of claim 28.

40. (Previously Presented) A monoclonal antibody of claim 28 which has a cross-reactivity with a rapamycin of less than 10%.

41. (New) The monoclonal antibody of claim 31 wherein the immunogenic protein is bovine serum albumin (BSA), ovalbumin (OVA), or keyhole limpet hemocyanine (KLH).